ROLE OF DUTASTERIDE IN DECREASING PERIOPERATIVE BLOOD LOSS DUE TO TRANSURETHRAL RESECTION OF PROSTATE

Abstract

Background: Benign prostatic hyperplasia (BPH) is a common urological condition in elderly men and transurethral resection of the prostate (TURP) is frequently associated with perioperative bleeding.

Objective: To evaluate the effect of six weeks of preoperative dutasteride on perioperative blood loss in patients undergoing TURP for BPH.

Methodology: The study was a randomized controlled trial with the aim of comparing the two drugs and to determine the safety of one of them for the treatment of erectile dysfunction, which was carried out in the Department of Urology-I, Armed Forces Institute of Urology, Rawalpindi, from August 2020 to February 2021. Twenty patients were enrolled for each group (A: dutasteride, B: control) of equal size (n = 200). Group A was treated with dutasteride 0.5 mg/day for 6 weeks before TURP surgery, whereas Group B was not treated before TURP surgery. Perioperative blood loss was estimated by the drop in Hb and transfusion requirement was noted. The data was analysed using SPSS version 23 software and the value p≤ 0.05 was taken to be significant.

Results: The mean hemoglobin drop was significantly lower in Group A (0.73 ± 0.18 g/dL) compared to Group B (1.69 ± 0.35 g/dL) (p < 0.001). Blood transfusion was required in 0 patients (0%) in Group A compared to 4 patients (4%) in Group B. Overall, 100 patients (100%) in Group A and 96 patients (96%) in Group B did not require transfusion.

Conclusion: Preoperative dutasteride effectively reduces perioperative blood loss and transfusion requirement in patients undergoing TURP for BPH.